A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer

Inclusion Criteria

• •Written informed consent
• •Male and female patients at least 18 years of age
• •Newly diagnosed Stage IIIB/C or IV non-small cell lung cancer (according to Revised Cancer Staging by American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) 8th edition) or recurrent non-small cell lung cancer (NSCLC)
• •Histologically or cytologically confirmed diagnosis of predominately non-squamous NSCLC
• •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• •Be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin based on local standard of care, for the treatment of advanced or metastatic non-squamous NSCLC
• •Presence of at least 1 measurable tumour as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
• •Neutrophils ≥ 1,5 × 10\^9/L
• •Platelets ≥ 100 × 10\^9/L
• •Haemoglobin ≥ 90 g/L
• •Bilirubin level ≤ 1.5 × upper limit of normal (ULN)
• •Aspartate-aminotransferase (AST) and alanine-aminotransferase (ALT) levels \< 3 × ULN (\< 5 × ULN for patients with liver metastases)
• •Alkaline phosphatase level \< 3 × ULN (\< 5 × ULN for patients with liver or bone metastases)